Mabwell has dosed the first patient in its Phase II anti-IL-11 antibody (9MW3811) clinical trial in China for pathological scarring.
This marks the first time an IL-11 targeted drug candidate has entered clinical trials for this indication globally.
The Phase II clinical trial is designed to evaluate the tolerability, safety, preliminary efficacy, and pharmacokinetics of 9MW3811.
Download sample pages of selected reports
Explore a selection of report samples we have handpicked for you. Get a preview of the insights inside. Download your free copy today.
The first patient received dosing at Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine.
Mabwell previously completed Phase I trials with 9MW3811 in healthy patients in China and Australia, reporting a favourable safety profile and a half-life of more than a month.
Interleukin-11 (IL-11) is a cytokine involved in fibrosis-related diseases and chronic inflammation, playing a role in the fibrosis process of multiple organs.
According to Mabwell, preclinical research has shown that 9MW3811 demonstrated marked efficacy in models such as pulmonary fibrosis and has potential application in fibrosis-related diseases like abnormal endometrial bleeding and hypertrophic scar.
In human-derived keloid animal models, 9MW3811 alleviated the skin fibrosis process and reduced the volume of established scars.
There are currently no effective therapeutic drugs for hypertrophic scars and keloids, revealing a significant unmet clinical need.
Mabwell noted that 9MW3811 will offer new treatment options for patients with these conditions.
Mabwell is a biopharmaceutical company with capabilities across the pharmaceutical value chain, focusing on ageing-related diseases and oncology.
In August 2024, the company received approval from China’s National Medical Products Administration (NMPA) to begin a Phase III clinical trial of 9MW2821 plus Toripalimab for treating urothelial carcinoma.
Unlock up to 35% savings on GlobalData reports
Use the code at checkout in the report store
-
20% OFF
Buy 2 reports
Use code:
Bundle20
-
25% OFF
Buy 3 reports
Use code:
Bundle25
-
30% OFF
Buy 4 reports
Use code:
Bundle30
-
35% OFF
Buy 5+ reports
Use code:
Bundle35
Valid on all reports priced $995 and above. Cannot be combined with other offers.
Still deciding what will work best for your business?
Ask our experts for help.
Enquire before buying
